CTOs on the Move

IDx Technologies

www.eyediagnosis.net

 
IDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

IDx Technologies raised $32.5M on 09/26/2018

Similar Companies

Jubilant Clinsys

Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs

Lumicks

LUMICKS is the leading supplier of Dynamic Single-Molecule and Cell Avidity analysis instruments` Our instruments enable – for the first time – the analysis of complex dynamic details related to the behavior and interaction of single molecules and cells` Built upon innovative and Nobel Prize-winning technologies, such as optical tweezers (Nobel Prize for Physics 2018), and STED super-resolution (Nobel Prize for Chemistry 2014), our tools enable the understanding of life to the smallest detail` Our goal is to improve human health by unlocking the power of Dynamic Single–Molecule and Cell Avidity analysis to provide unparalleled insight into the fundamental cause of disease and potential for drug optimization` These technologies are rapidly evolving as a mainstream approach in academic and pharma research for the study of DNA-protein interactions, molecular motor activity, protein folding, and cell-cell interactions`

www.velosbio.com

VelosBio, Inc. operates as a biotechnology firm specializing in oncology.

Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea`s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.

Molecular Therapeutics

Molecular Therapeutics is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.